We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-10.3%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.69B
AUM Growth
-$784M
Cap. Flow
+$36.9M
Cap. Flow %
1%
Top 10 Hldgs %
43.31%
Holding
160
New
14
Increased
20
Reduced
11
Closed
10

Top Buys

Rank Stock Value
1
EQRX
EQRx, Inc. Common Stock
EQRX
+$37.8M
2
KYMR icon
Kymera Therapeutics
KYMR
+$34.9M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$31.1M
4
EVO icon
Evotec
EVO
+$26.8M
5
BLU
BELLUS Health Inc.
BLU
+$21.6M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$172M
2
ARGX icon
argenx
ARGX
+$23.5M
3
ITOS
iTeos Therapeutics
ITOS
+$15M
4
BABA icon
Alibaba
BABA
+$14.8M
5
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$14.1M

Sector Composition

Rank Sector Weight
1 Healthcare 83.88%
2 Miscellaneous 7.67%
3 Consumer Discretionary 6.51%
4 Financials 0.7%
5 Materials 0.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLMA icon
126
Olema Pharmaceuticals
OLMA
$856M
$2.44M 0.07%
260,500
– –
MREO
127
Mereo BioPharma
MREO
$45.5M
$2.4M 0.07%
1,500,000
– –
ORTX
128
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$2.38M 0.06%
180,386
– –
CDAK
129
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$2.23M 0.06%
200,000
– –
KNTE
130
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.21M 0.06%
125,000
– –
HIPO icon
131
Hippo Holdings
HIPO
$859M
$1.7M 0.05%
24,000
– –
AMYT
132
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$1.63M 0.04%
150,480
– –
AXLA
133
DELISTED
Axcella Health Inc. Common Stock
AXLA
$1.49M 0.04%
28,500
– –
HOOK
134
DELISTED
HOOKIPA Pharma
HOOK
$1.4M 0.04%
59,962
– –
INKT icon
135
MiNK Therapeutics
INKT
$58.2M
$1.29M 0.04%
+28,959
New +$3.44M
IRWD icon
136
Ironwood Pharmaceuticals
IRWD
$671M
$1.29M 0.04%
110,532
– –
CRVS icon
137
Corvus Pharmaceuticals
CRVS
$1.09B
$1.21M 0.03%
500,000
– –
KLDO
138
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$1.2M 0.03%
500,500
– –
LVTX
139
DELISTED
LAVA Therapeutics
LVTX
$1.1M 0.03%
200,000
– –
DCPH
140
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$977K 0.03%
100,000
– –
RIGL icon
141
Rigel Pharmaceuticals
RIGL
$829M
$851K 0.02%
32,110
– –
SGTX
142
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$762K 0.02%
21,231
– –
MBII
143
DELISTED
Marrone Bio Innovations, Inc.
MBII
$755K 0.02%
+1,048,679
New +$848K
RIVN icon
144
Rivian
RIVN
$22.5B
$726K 0.02%
+7,000
New +$807K
DLO icon
145
dLocal
DLO
$4.25B
$714K 0.02%
+20,000
New +$865K
KA
146
DELISTED
Kineta, Inc. Common Stock
KA
$643K 0.02%
31,056
– –
MTCR
147
DELISTED
Metacrine, Inc. Common Stock
MTCR
$624K 0.02%
924,898
– –
SURF
148
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$478K 0.01%
100,000
– –
CDTX
149
DELISTED
Cidara Therapeutics
CDTX
$285K 0.01%
11,234
– –
ATXS
150
DELISTED
Astria Therapeutics
ATXS
$180K ﹤0.01%
33,333
– –
3 4 5
6
7

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2021 Portfolio in Review

As of Q4 2021, Artal Group held 160 positions worth $3.69B, down 18% from $4.47B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group's Q4 2021 filing shows 14 new, 20 increased, 11 reduced and 10 closed positions. Its largest new stake was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M. The largest sale was Acceleron Pharma, an estimated $172M.

By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Artal Group's largest Q4 2021 buy was EQRx, Inc. Common Stock: 4,000,000 shares worth $27.3M.
  • Artal Group added most to Kymera Therapeutics in Q4 2021, an estimated $34.9M increase.
  • Artal Group's biggest Q4 2021 reduction was argenx, cutting an estimated $23.5M.
  • Artal Group fully exited Acceleron Pharma in Q4 2021, selling an estimated $172M.
  • Artal Group's ten largest holdings make up 43% of its $3.69B portfolio in Q4 2021.
  • Artal Group opened 14 new positions and closed 10 in Q4 2021.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.69B.

Based on Artal Group's 13F filing for Q4 2021, filed 11 Feb 2022.